ICG-guided bowel perfusion assessment ( DrugBank: - )
1 disease
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
96 | Crohn disease | 1 |
96. Crohn disease
Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04712032 (ClinicalTrials.gov) | July 1, 2020 | 14/1/2021 | Anastomotic Leakage and Value Of Indocyanine Green in Decreasing Leakage Rates | A PHASE III, RANDOMISED CONTROLLED TRIAL ASSESSING THE VALUE OF INDOCYANINE GREEN IN THE LEAKAGE RATE OF COLORECTAL ANASTOMOSES | Colo-rectal Cancer;Crohn Disease;Resectable Colorectal Carcinoma | Drug: ICG-guided bowel perfusion assessment | Leiden University Medical Center | Medical Center Haaglanden;Catharina Ziekenhuis Eindhoven;Haga Hospital;Jeroen Bosch Ziekenhuis;Amphia Hospital;Alrijne Hospital;IJsselland | Recruiting | 18 Years | N/A | All | 978 | Phase 3 | Netherlands |